A multicenter phase II study of INTRON, recombinant alpha-2 interferon (Schering Corp, Kenilworth, NJ), in @entity1 with relapsing or refractory @entity1582 was initiated. @entity1 received either intravenous therapy for two weeks followed by subcutaneous therapy or subcutaneous dosing from initiation of treatment. Of 38 evaluable @entity1 , 19 were refractory and 19 had relapsed at entry. Twenty-five of 38 had received prior treatment with multiple drugs. Responses were seen among 2/19 refractory @entity1 and 5/19 relapsing @entity1 . Three of seven responders continue to respond for more than one year while receiving maintenance therapy. Most @entity1 experienced improvement in @entity158 , and one @entity1 , with a complete response, had healing of @entity79 . Survival curves show a statistically significant improvement in survival for responders v nonresponders. INTRON was well-tolerated with only four @entity1 discontinuing treatment due to adverse effects. Thirty-two percent of @entity1 had @entity1503 requiring dose adjustment; however, there was no evidence of cumulative @entity1503 . No patients developed serum neutralizing factors to interferon. Additional trials are warranted to study the activity of INTRON in previously untreated @entity1 .

Phase II study of recombinant alpha-2 interferon in resistant multiple XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['myeloma'] @entity79 :: ('MESH:D001847', 'Disease') :: ['bone lesions'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['hematologic toxicity'] @entity158 :: ('MESH:D010146', 'Disease') :: ['bone pain']
@entity1582 :: (MESH:D009101,Disease) :: ['myeloma']
